72995-15-4

Basic information

• Product Name: 5-chloro-3,4-dihydroquinolin-2(1H)-one
• Synonyms: 5-chloro-3,4-dihydroquinolin-2(1H)-one;5-chloro-3,4-dihydro-2(1H)-quinolinone;2(1H)-Quinolinone, 5-chloro-3,4-dihydro-;5-chloro-3,4-dihydro-1H-quinolin-2-one
• CAS NO: 72995-15-4
• Molecular Formula: C9H8ClNO
• Molecular Weight: 181.61892
• Mol File: 72995-15-4.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 355.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.290±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.04±0.20(Predicted)
• CAS DataBase Reference: 5-chloro-3,4-dihydroquinolin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-3,4-dihydroquinolin-2(1H)-one(72995-15-4)
• EPA Substance Registry System: 5-chloro-3,4-dihydroquinolin-2(1H)-one(72995-15-4)

Safety Data

• Hazardous Substances Data: 72995-15-4(Hazardous Substances Data)

Usage

General Description

5-chloro-3,4-dihydroquinolin-2(1H)-one is a chemical compound with the molecular formula C9H8ClNO. It is an organic compound that belongs to the quinoline family, which is commonly found in various pharmaceuticals and agrochemicals. 5-chloro-3,4-dihydroquinolin-2(1H)-one is known for its potential medicinal properties and is often used as a building block in the synthesis of different pharmaceutical drugs. It is also used as an intermediate in the production of various organic compounds. The presence of a chlorine atom and a carbonyl group in its structure makes 5-chloro-3,4-dihydroquinolin-2(1H)-one an important compound in the field of organic chemistry with a wide range of applications.

Upstream product

• 126401-55-6 5amino-3,4-dihydro-2(1H)-quinolinone hydrochloride 
• 1643-28-3 3-(2-chlorophenyl)propanoic acid 
• 70237-25-1 3-chloro-2-iodobenzenamine 
• 2177-67-5 methyl 2-ethylacrylate 
• 292638-85-8 acrylic acid methyl ester 
• 201230-82-2 carbon monoxide 
• 301645-40-9 1-chloro-3-nitro-2-vinylbenzene 
• 1247021-83-5 diethyl (2-amino-6-chlorobenzyl)propanedioate 
• 333954-56-6 diethyl 2-[(2-chloro-6-nitro-phenyl)methyl]propanedioate 
• 32337-97-6 1-chloro-2-iodo-3-nitrobenzene 
• 769-11-9 2-chloro-6-nitroaniline 
• 83-42-1 6-chloro-2-nitrotoluene 
• 121-73-3 3-Nitrochlorobenzene 
• 140-88-5 ethyl acrylate 

Downstream Products

• 72995-16-5 5-chloro-1,2,3,4-tetrahydroquinoline 
• 882023-24-7 2-oxo-1,2,3,4-tetrahydroquinoline-5-carbonitrile 
• 182954-78-5 5-Chloro-1-{3-[4-(3-nitrophenyl)-1-piperazinyl]propyl}-3,4-dihydrocarbostyril 
• 145969-63-7 1-{3-[4-(3-aminophenyl)-1-piperazinyl]propyl}-5-chloro-3,4-dihydrocarbostyril 

Relevant articles and documents

2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

The disclosure provides an aminopyrimidine derivative for preventing and treating diseases related to IDH mutation, a preparation method and use thereof. Specifically, the disclosure provides a compound of Formula I, a stereoisomer, racemate thereof, or pharmaceutically acceptable salt thereof. The compound of the general Formula I has isocitrate dehydrogenase 1 (IDH1) inhibitory activity and can treat cancer induced by IDH1 mutation.

Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration

Isocitrate dehydrogenase 1 (IDH1), which catalyzes the conversion of isocitrate to α-ketoglutarate, is one of key enzymes in the tricarboxylic acid cycle (TCA). Hotspot mutation at Arg132 in IDH1 that alters the function of IDH1 by further converting the α-ketoglutarate(α-KG) to 2-hydroxyglutarate (2-HG) have been identified in a variety of cancers. Because the IDH1 mutations occur in a significant portion of gliomas and glioblastomas, it is important that IDH1 inhibitors have to be brain penetrant to treat IDH1-mutant brain tumors. Here we report the efforts to design and synthesize a novel serial of mutant IDH1 inhibitors with improved activity and the blood-brain barrier (BBB) penetration. We show that compound 5 exhibits good brain exposure and potent 2-HG inhibition in a HT1080-derived mouse xenograft model, which makes it a potential preclinical candidate to treat IDH1-mutant brain tumors.

NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R10, R11, R12, R13, R14, R15, R16, R17 and m are as described herein, compositions including the compounds and methods of using the compounds.